Technology areas: Biotechnology & Pharmaceuticals • Transportation, E-Commerce & Mechanical Systems
5 pending office actions • 5 art units • 5 examiners • 0 of 5 (0%) have an AI response strategy ready • 4 patents granted in the last 365 days
BPGbio, Inc. has 5 pending office actions in Biotechnology & Pharmaceuticals. The matters involve 5 examiners and 5 art units, placing each application in a separate examination assignment.
GONZALEZ, LUISALBERTO is the busiest examiner, with 1 pending matter. The docket calls for application-specific analysis, supported by centralized coordination of biotechnology terminology and technical evidence.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 only | 1 (20%) |
| §101 + other | 1 (20%) |
| §103 only | 1 (20%) |
| Double-patenting + other | 2 (40%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| GONZALEZ, LUISALBERTO | 1 | 58.5% | +48.3% |
| YOUNGBLOOD, WILLIAM JUSTIN | 1 | 59.5% | +42.0% |
| SANG, HONG | 1 | 54.9% | +62.8% |
| EVANS, ASHLEY ELIZABETH | 1 | 17.2% | +38.5% |
| CLOW, LORI A | 1 | 64.2% | +28.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18290575 | METHODS AND MARKERS FOR DIAGNOSIS OF PARKINSON'S DISEASE | EVANS, ASHLEY ELIZABETH | 85d overdue |
| 18125524 | INTERROGATORY CELL-BASED ASSAYS AND USES THEREOF | CLOW, LORI A | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18290575 | METHODS AND MARKERS FOR DIAGNOSIS OF PARKINSON'S DISEASE | EVANS, ASHLEY ELIZABETH | 85d overdue |
| 18711570 | COMPOUNDS FOR USE IN TREATING GASTRIC CANCER | GONZALEZ, LUISALBERTO | — |
| 18635905 | MICROTUBULE TARGETING AGENTS | YOUNGBLOOD, WILLIAM JUSTIN | — |
| 18523239 | FILAMIN A BINDING PROTEINS AND USES THEREOF | SANG, HONG | — |
| 18125524 | INTERROGATORY CELL-BASED ASSAYS AND USES THEREOF | CLOW, LORI A | — |
| Art Unit | Apps |
|---|---|
| 1624 | 1 |
| 1629 | 1 |
| 1646 | 1 |
| 3687 | 1 |
| 1671 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18711570 | COMPOUNDS FOR USE IN TREATING GASTRIC CANCER | GONZALEZ, LUISALBERTO | 1624 | §103 | Final Rejection | — | Pending | May 17, 2024 |
| 18635905 | MICROTUBULE TARGETING AGENTS | YOUNGBLOOD, WILLIAM JUSTIN | 1629 | §102DP | Final Rejection | — | Pending | Apr 15, 2024 |
| 18523239 | FILAMIN A BINDING PROTEINS AND USES THEREOF | SANG, HONG | 1646 | §102§103§112DP | Non-Final OA | — | Pending | Nov 29, 2023 |
| 18290575 | METHODS AND MARKERS FOR DIAGNOSIS OF PARKINSON'S DISEASE | EVANS, ASHLEY ELIZABETH | 3687 | §101§102§103 | Final Rejection | 85d overdue | Pending | Nov 14, 2023 |
| 18125524 | INTERROGATORY CELL-BASED ASSAYS AND USES THEREOF | CLOW, LORI A | 1671 | §101Other | Non-Final OA | — | Pending | Mar 23, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialBPGbio, Inc. has 5 pending office actions as of November 2026, spread across 5 art units and 5 examiners.
Luisalberto Gonzalez has the most, with 1 of BPGbio, Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.